No unexpected safety issues have arisen to date, and the established safety profile for semaglutide is similar to that of other GLP-1RAs where definitive conclusions for pancreatic and thyroid cancer cannot be drawn at this point due to low incidence of these conditions.4 Conclusion Semaglutide has shown significant weight reduction of up to 20%, as well as other significant health benefits seen in cardiovascular disease, stroke, and kidney function in clinical trials over long term use
Not designed for rapid or significant weight reduction
The renal function should be monitored continuously after escalating the dose of Semaglutide
The FDA label carries warnings about primary pulmonary hypertension and valvular heart disease, though these are rare
Such letters may also be required if your insurance company includes weight loss medications in its formulary but denies you coverage
In plain English, a peptide is a short chain of amino acids, which are the building blocks of proteins